© 2021 MJH Life Sciences and Contagion Live. All rights reserved.
© 2021 MJH Life Sciences™ and Contagion Live. All rights reserved.
January 08, 2021
Therapies in the pipeline to treat C. difficile and closing thoughts on what is most exciting, in regards to better prevention and management of the condition, moving forward.
Current barriers associated with the use of fecal microbiota transplantation for C. difficile infections.
Healthcare experts comment on current data associated with emerging microbiota therapies that are currently under study for the treatment of C. difficile infections.
Panelists discuss the use of fecal microbiota transplantation as treatment for eligible patients with C. difficile.
Current gaps in the prevention/treatment of C. difficile infections, as highlighted by leading healthcare professionals.
The rationale for using bezlotoxumab as treatment for certain patients with C. difficile infections and current limitations that are impacting its use in clinical practice.
Implications for prescribing vancomycin or fidaxomicin to treat C. difficile infections.
A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.
Important factors to consider when selecting an appropriate therapy to treat C. difficile.
Implications regarding how to properly treat patients with C. difficile infections based on data that has emerged since clinical practice guidelines were last updated.